Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago CAR-T

Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward

Liver cancer, CAR-T

CT011

On January 15, 2024, #CARsgen Pharmaceuticals announced that its autologous #CARTcell candidate product #CT011, targeting Glypican-3 (GPC3), has been approved for clinical use in China. It is intended for the treatment of GPC3-positive stage IIIa hepatocellular carcinoma patients at risk of recurrence after surgical resection.

Glypican-3 (GPC3)

Glypican-3 (GPC3)plays a crucial role in regulating cell growth and differentiation and is closely associated with the occurrence and progression of liver cancer. GPC3 is expressed in reproductive system tumors such as hepatocellular carcinoma, ovarian clear cell carcinoma, and yolk sac tumors. Its expression rate in hepatocellular carcinoma reaches 74.8%, while it is virtually absent in normal liver tissue, making it an ideal new target for #livercancer #CARTtherapy.

Promising Target

Due to its tumor specificity, GPC3 is considered a promising target for cancer immunotherapy. Higher expression of GPC3 in hepatocellular carcinoma is associated with poorer prognosis.

Frontiers in Immunology

In August 2022, a Chinese medical team published a long-term survival case report of treating advanced hepatocellular carcinoma with CT011 in the journal “#FrontiersinImmunology.” The study reported complete remission (#CR) and long-term survival in a patient with advanced hepatocellular carcinoma after receiving GPC3 CAR-T cell therapy in combination with the multi-target kinase inhibitor sorafenib.

Results showed good tolerance to CT011 combined with sorafenib treatment. The patient achieved partial remission (PR) from the third month onwards and attained complete remission at the 12th month after the first CT011 infusion. The tumor did not progress for over 36 months, maintaining complete remission status for over 24 months after the first infusion.

Cancer Communications

On October 12, 2023, CARsgen Pharmaceuticals announced the clinical efficacy of its independently developed CAR-T cell therapy targeting GPC3 in two patients with advanced hepatocellular carcinoma (HCC). The clinical trial results were published in “#CancerCommunications.” Both patients had inferior prognostic outcomes upon enrollment, with one having inferior vena cava tumor thrombus and the other having retroperitoneal lymph node metastasis.

In the clinical trial, one patient received local treatment for intrahepatic recurrent tumors and inferior vena cava tumor thrombus (microwave ablation and gamma knife) before receiving CAR-T cell therapy targeting GPC3. Six months later, AFP (alpha-fetoprotein) levels normalized, and imaging revealed no active tumors. The other patient underwent local treatment (microwave ablation and gamma knife) for controlling intrahepatic tumors, inferior vena cava tumor thrombus, and peritoneal lymph node metastases while receiving CAR-T cell therapy.

Encouragingly, both patients showed significant efficacy after combined local treatment and CAR-T cell infusion, maintaining tumor-free status during long-term follow-up, with both individuals being tumor-free for over 7 years. Throughout the follow-up period, both patients only received oral antiviral therapy for hepatitis B and did not undergo any other cancer treatment.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CART #Immunotherapy #LiverCancer #CancerResearch #MedicalInnovation #Healthcare #ClinicalTrials #SurvivorStories #GPC3 #PrecisionMedicine

7 months ago patient story , CAR-T

Expert Perspective: Options for CAR-T Therapy in Thai Patients

🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈

🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.

🌼We will continue to follow up on the patient’s treatment progress and provide further updates.

#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory

7 months ago patient story

🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀

ЧудесноеПутешествие

🌿Познакомьтесь с мистером Баранковым,

68-летним пациентом из Санкт-Петербурга, Россия, который внезапно был диагностирован с множественной миеломой в 2018 году. После четырех лет международных консультаций он обнаружил, что Китай значительно продвинулся в области терапии CAR-T по сравнению с европейскими медицинскими учреждениями в Испании, Мюнхене, Гейдельберге и других странах. Результаты лечения в Китае ведущие в мире.

🌱После четырех лет лечения и рецидивов

После неудачной традиционной химиотерапии и двух автологичных трансплантаций гемопоэтических стволовых клеток, у него появилась возможность провести онлайн-консультацию с экспертами Международной больницы Цзяхуи в Шанхае. Во время виртуальной консультации господин Баранков был впечатлен опытом китайской медицинской команды и потенциалом лечения с помощью полностью человеческого препарата CAR-T FUCASO (Eque-cel). Учитывая лидирующее положение Китая в области терапии CAR-T, более конкурентоспособные затраты и относительно короткое время ожидания, господин Баранков принял решение отправиться в Китай для получения лечения.

☘️
#ЧудесноеПутешествие #ТерапияCART #ПересечениеГраниц #MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago patient story

🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀

Hope of patients

🌱Meet Mr. Barankov

a 68-year-old patient from Saint Petersburg, Russia, who was unexpectedly diagnosed with multiple myeloma in 2018. After four years of international consultations, he discovered that China has made significant advancements in CAR-T therapy compared to European medical institutions in Spain, Munich, Heidelberg, and others.

🌿The treatment outcomes in China are leading globally.

Following unsuccessful traditional chemotherapy and two autologous hematopoietic stem cell transplants, he had the opportunity for an online consultation with experts from Jiahui International Hospital in Shanghai. During the virtual consultation, Mr. Barankov was impressed by the expertise of the Chinese medical team and the therapeutic potential of the fully human CAR-T drug FUCASO (Eque-cel). Considering China’s leading position in CAR-T therapy, more competitive costs, and relatively shorter wait times, Mr. Barankov made a significant decision to travel to China for treatment.

☘️#MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago

Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy

Lymphoma

Ruijin Hospital,

affiliated with Shanghai Jiao Tong University School of Medicine, announced that with continuous exploration in clinical practice, experts have made progress in CAR-T cell therapy for lymphoma, benefiting an increasing number of patients. This advancement is of significant importance for further promoting and expanding the application of CAR-T therapy, allowing more patients to benefit from it.

Lymphoma

is a malignant tumor originating from the lymphatic hematopoietic system and encompasses a family of nearly a hundred different subtypes. Relapse and drug resistance pose major challenges for patients. CAR-T products have the potential to improve treatment outcomes and facilitate the broader application of CAR-T therapy among a wider range of patients in China.

CAR-T therapy

involves genetically modifying T cells to equip them with the ability to recognize tumors, enabling them to kill cancer cells in the body. If natural T cells can be likened to “ordinary soldiers,” then CAR-T cells can be considered as “special forces.” For cancer patients, the 5-year survival rate is an important milestone and a signal of cancer being cured. Achieving a 5-year survival implies that some cancer patients treated with CAR-T therapy can obtain long-term survival without further anticancer drug treatment, truly achieving the possibility of “cancer being cured.” Aunt Qin, the first patient enrolled in China’s CAR-T registered clinical trial in 2018, has achieved sustained complete remission for over 5 years and is about to enter the 6th year.

100th patient

At Ruijin Hospital, the 100th patient with relapsed/refractory lymphoma treated with CAR-T therapy has achieved complete remission and been discharged. The patient, Ms. Xu (alias), is a 41-year-old woman who now has a healthy complexion. She was initially diagnosed with follicular lymphoma and underwent chemotherapy and targeted therapy. However, the disease relapsed three months later, transforming into high-grade B-cell lymphoma. High-grade B-cell lymphoma is highly malignant with a poor prognosis. Professor Zhao Weili from the Hematology Department at Ruijin Hospital conducted a detailed analysis of Ms. Xu’s condition and developed a treatment plan for her. On November 22, 2023, after receiving CAR-T cell infusion, Ms. Xu showed complete remission of the tumor during the follow-up examinations at one month and three months.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

Email: doctor.huang@globecancer.com

or WhatsApp+8613717959070

The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #RuijinHospital #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

7 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – 🔥Long-term efficacy 🔥

🌎Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– 🔥Long-term efficacy 🔥

multiple myeloma

🌙China has made significant breakthroughs in the treatment of multiple myeloma with BCMA CAR-T therapy, attracting global attention. Recently, two fully human BCMA CAR-T therapies, Equecabtagene Autoleucel and Zevorcabtagene Autoleucel, have been approved for the treatment of relapsed/refractory multiple myeloma.⭐️

🌛 In terms of long-term efficacy, for patients with a CAR-T cell persistence of over one year, the percentage is 53.3% for Equecabtagene Autoleucel and 26.5% for Zevorcabtagene Autoleucel at six months’ persistence.⭐️

🌜The duration of CAR-T cell persistence has an impact on the survival outcome of multiple myeloma (MM) patients. Long-term follow-up data from the Lengend-2 study showed a significant improvement in the cumulative overall survival (OS) rate for RRMM patients with a CAR-T cell persistence of over 280 days compared to patients with a persistence of less than 280 days. Therefore, 280 days of persistence is a critical threshold for improving clinical outcomes.⭐️

✨The median persistence for Zevorcabtagene Autoleucel is 77 days, while for Equecabtagene Autoleucel, it is 419 days, far exceeding the critical threshold. It is expected to improve the OS of MM patients.⭐️

🌤From a clinical perspective, both therapies demonstrate a trend of improving long-term efficacy over time.

The complete response (CR) rate at six months of follow-up is 54.8% for Equecabtagene Autoleucel and 35.0% for Zevorcabtagene Autoleucel.⭐️

🌝At a median follow-up of around nine months, the registered clinical data from China shows a CR rate of ≥74.2% for Equecabtagene Autoleucel and 45.1% for Zevorcabtagene Autoleucel.⭐️

🌞During the 2023 IMS conference, Equecabtagene Autoleucel presented the latest long-term follow-up data, revealing a further increase in the CR rate to 82.4% at a median follow-up of 18.07 months.⭐️

☀️The efficacy data following a median follow-up of nine months for Zevorcabtagene Autoleucel in the registered clinical trial LUMMICAR-1 Phase 2 study has not been publicly disclosed.

China’s breakthroughs in CAR-T cell therapy are remarkable. It not only provides new treatment options for multiple myeloma patients but also demonstrates China’s strength in medical research and innovation. It brings hope and possibilities for improving patients’ survival and quality of life.⭐️

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical

7 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – Short-term efficacy

Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– Short-term efficacy

multiple myeloma

China CAR-T therapy

In recent years, CAR-T cell therapy has achieved tremendous success in treating hematologic malignancies. Over the past 11 years, China has seen a surge in clinical trials evaluating the safety and efficacy of CAR-T therapy. China has now surpassed the United States as a major force in CAR-T clinical research.

In the field of multiple myeloma (MM),

China has gained regulatory approval from the NMPA for two fully human BCMA CAR-T therapies for the treatment of relapsed/refractory MM (R/R MM). These therapies are Equecabtagene Autoleucel and Zevorcabtagene Autoleucel.

BCMA

While both therapies target the same BCMA and share a common co-stimulatory domain, there are some fundamental differences between them. Zevorcabtagene Autoleucel includes patients with stable disease after previous treatment, whereas Equecabtagene Autoleucel focuses on patients with relapsed or progressive MM.

Looking at the short-term efficacy

The median time to peak CAR-T cells in peripheral blood is 12 days for Equecabtagene Autoleucel and 14 days for Zevorcabtagene Autoleucel. This indicates that the former can rapidly exert its effect, potentially laying the foundation for achieving clinical remission faster and better.

Clinical trial results seem to support this notion, with Equecabtagene Autoleucel showing a median time to response (TTR) of 15 days, compared to 29 days for Zevorcabtagene Autoleucel. At the 3-month follow-up, the complete remission rates were 40.3% for Equecabtagene Autoleucel in the registered clinical trial FUMANBA-1 1b/2 phase, surpassing the rate of 28.3% observed in the registered clinical trial LUMMICAR-1 phase 2 for Zevorcabtagene Autoleucel.

It’s worth noting that the infusion dose for Equecabtagene Autoleucel is 1×106 cells/kg, while the total infusion dose for Zevorcabtagene Autoleucel is 150×106 cells, which translates to double the dose of Equecabtagene Autoleucel for patients with a weight of 70kg-75kg. Additionally, the reinfusion dose for Zevorcabtagene Autoleucel is not fixed and needs to be increased to 1.8×108 cells for patients weighing ≥80kg.

With the increasing availability of these groundbreaking BCMA CAR-T therapies, the landscape of multiple myeloma treatment continues to expand, offering more possibilities and choices.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical Advanced Medicine in China

7 months ago Myeloma

Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy

Multiple Myeloma

Singaporean patient, Teresa has been battling multiple myeloma for nearly three years. Despite undergoing various conventional treatments including multi-drug therapy, radiation, and chemotherapy, her condition relapsed with extramedullary plasmacytomas affecting her brain, liver, and multiple bones. Recently, after an online consultation with Dr. Vicky Lee and her team at Shanghai Jiahui International Hospital, she made a significant decision: to undergo FUCASO CAR-T therapy in China.

China not only possesses global-leading clinical experience in CAR-T therapy but also offers high-quality commercialized CAR-T products at a competitive price in the global market. Currently, there is an ample supply of these CAR-T products available in China, which is crucial for patients racing against time. Furthermore, the convenience of a single infusion has attracted international attention.

At Shanghai Jiahui International Hospital, an experienced team of hematologic oncology specialists will tailor a personalized treatment plan for Teresa, providing comprehensive and refined diagnostic and therapeutic services. As a pioneer in CAR-T therapy, Jiahui Hospital is about to bring new hope to Ms. Teresa.

We will continue to monitor Teresa’s treatment progress and provide updates.

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

7 months ago Myeloma

$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

🌈 $160,000 per dose! 🌈

⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

multiple myeloma

Zevor-cel

🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.

Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.

Cheapest CAR-T therapy

🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).

US CAR-T

🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.

Multiple Myeloma

🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.

In China

⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.

🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine

#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients

8 months ago CAR-T

The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%!

✨ The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%! ✨

multiple myeloma

🌟BCMA (also known as CD269) and GPRC5D, these two targets are revolutionizing the treatment landscape of multiple myeloma (MM). BCMA is one of the hottest targets for treating MM currently, while GPRC5D is poised to be a potent complement to BCMA.

🔍 About BCMA: CAR-T Therapy with Remission Rates Exceeding 90%!

👩‍⚕️BCMA is primarily expressed on the surface of terminally differentiated B cells, making it a promising new target in hematologic malignancies treatment. Currently, both in clinical trials and marketed BCMA-targeted CAR-T therapies have shown significant efficacy, with some second-generation CAR-T projects achieving remission rates of over 90%, and the remission rates of domestically produced CAR-T products are also leading globally.

Among domestically produced CAR-T therapies in China,

🌟The marketed injection of Cilta-cel (Carvykti) has an overall remission rate of 89.6% and a complete remission rate of 77.1%.

🌟The fully human Equecabtagene Autoleucel injection (developed by the highly regarded Chinese company IASO Bio) boasts an overall remission rate of 98.9%, with a complete remission rate of 82.4%.

🌟Additionally, recent follow-up data from the ASH conference showed that Zevor-cel, developed by Chinese company CARsgen and just approved for market in China, has an overall remission rate of 100%, with a complete remission rate of 92.9%.

💡 About GPRC5D: A New Hopeful Treatment Target!

🔬About 65% of MM patients exhibit high expression of GPRC5D, and its expression is relatively independent of BCMA. The development speed of domestically produced CAR-T projects in China is considerable. For example, OriCAR-017, a CAR-T product developed by a domestic pharmaceutical company, achieved an overall remission rate of 100% in 10 trial patients, with a strict complete remission rate of 60%.

🩺China is rapidly advancing in the field of CAR-T therapy, leading the way in both technological development and clinical applications. In the future, we will witness more “miracles of healing” created by these novel cell therapies.

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.

We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

#MultipleMyeloma #BCMA #GPRC5D #CART #CellTherapy #MiraclesOfHealing #CARTcell

8 months ago Myeloma

Breaking News Alert! Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China!

🚀 Breaking News Alert! 🚀

🎉 Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China! 🎉

multiple myeloma

CARsgen

🔍On March 1st, 2024, CARsgen, a leading Chinese pharmaceutical company, proudly announced the official approval by the National Medical Products Administration (NMPA) of their innovative CAR-T cell immunotherapy product, Zevor-cel, targeting BCMA. This revolutionary treatment is specifically designed for adult patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.

Zevor-cel

🌟 Zevor-cel marks CARsgen’s debut commercial product, promising a new ray of hope for patients. While the price remains undisclosed, anticipation is high as it is expected to be competitive with its counterparts. Stay tuned as we eagerly await the reveal of its pricing strategy!

💪At the 2023 ASH Annual Meeting, Zevor-cel’s impressive three-year follow-up data stole the spotlight, boasting a remarkable Overall Response Rate (ORR) of 100% and a median Progression-Free Survival (PFS) of 25.0 months. With a median Overall Survival (OS) yet to be reached, the two-year OS rate has already hit 100%, and the three-year OS rate stands at a remarkable 92.9%, underscoring its outstanding safety profile and offering renewed hope for patients battling relapsed or refractory multiple myeloma.

Multiple Myeloma

👍In terms of approved indications, it’s worth noting that the current portfolio of domestic CAR-T therapies in China caters to various hematologic malignancies. While FOSUNKITE and JW Therapeutics target lymphomas, JUVENTAS focuses on leukemia. CARsgen and IASO Bio, however, have set their sights on multiple myeloma, aligning perfectly with the pressing medical needs of patients in this category.

👏Let’s celebrate this remarkable milestone in the fight against multiple myeloma, as we continue to strive for better, more effective treatments to improve patients’ lives worldwide! 🌍 #TogetherWeCanBeatCancer

If you are interested in the latest cancer-fighting technologies and treatment methods in China, or if any of patients wish to learn more, our team is available to support and advise you and your patients at any time.

Website：[https://www.medtourcn.com/]

Whatsapp：+8613717959070

Email: doctor.huang@globecancer.com

🔍 #Zevorcel #CARsgen #MultipleMyeloma #CARTTherapy #MedicalBreakthrough #NMPAApproval #HopeForPatients #HealthcareInnovation #CancerTreatment #MedicalAdvancement

8 months ago Myeloma , CAR-T

Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy

🎯Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy🎯

⭐ Recently, Professor Li Ping’s team at Tongji Hospital in Shanghai successfully carried out Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) treatment for a relapsed and refractory multiple myeloma (R/RMM) patient. This therapy brings new hope for the treatment of R/RMM patients.🌟 The patient who underwent CAR-T treatment was diagnosed with multiple myeloma in Thailand in July 2021. With a high tumor burden and aggressive disease, despite receiving systemic chemotherapy, monoclonal antibodies, autologous hematopoietic stem cell transplantation (ASCT), and other treatments, the disease recurred multiple times. Within just 2 years of the disease course, the patient developed resistance to multi-line treatments, making it difficult to control the disease effectively.

🌠 As the number of relapses increases in R/RMM patients and the number of treatment lines expands, the response to treatment worsens, and the duration of remission becomes shorter. However, with the approval of the world’s first fully human CAR-T therapy drug, FUCASO (Eque-cel), in mainland China, new hope has undoubtedly been ignited for the treatment of multiple myeloma. Its breakthrough fully human CAR structure not only has low immunogenicity but also rapid dissociation and low exhaustion, allowing patients to return to a higher quality of life with just one treatment.

☄ After evaluation by Professor Li Ping’s team, the patient met the criteria for CAR-T cell therapy. After thorough communication between doctors and the patient and their family, the patient ultimately chose to undergo CAR-T therapy and completed peripheral blood mononuclear cell collection in November 2023.

✨ We will continue to monitor the patient’s treatment progress and provide follow-up reports.

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Note: Imaging and data have been authorized by the hospital, patients, and patients’ families.

Menu

Tags Archives: CAR-T therapy